Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Bests Market Segment Report: Record Catastrophe Bond Issuance Boosts ILS Capacity and Reshapes Pricing Landscape
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Reinsurance pricing at the midyear 2025 renewals was the most…
